SynthesisPharmacoEconomics2016
Economic Evaluations of Opioid Use Disorder Interventions.
Synthesis in PharmacoEconomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Cost per Opioid-Free Year: A Systematic Review and Summary Analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025Pooled it
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2022Guideline
- Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Pooled it
- Economic Evaluation in Opioid Modeling: Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Pooled it
- Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future.Journal of substance abuse treatment · 2020Pooled it
- Cost-Effectiveness of Linkage Case Management for Hospitalized People With HIV.JAMA network open · 2025Trial
- Health care use and cost of treatment for adolescents and young adults with opioid use disorder.Journal of substance use and addiction treatment · 2023Trial
- Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration.Addiction science & clinical practice · 2023Trial
- Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.Journal of substance abuse treatment · 2022Trial
- Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.Addiction (Abingdon, England) · 2021Trial
- Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults.Journal of substance abuse treatment · 2021Trial
- Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.Annals of internal medicine · 2019Trial
- Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.The American journal of managed care · 2018Trial
- Cost-effectiveness of emergency department-initiated treatment for opioid dependence.Addiction (Abingdon, England) · 2017Trial
- Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.Addiction (Abingdon, England) · 2017Trial
- Real-world comparative effects of slow-release oral morphine vs. methadone on healthcare use for opioid use disorder: A population-based target trial emulation.Addiction (Abingdon, England) · 2026Article
- Receipt of Pharmacotherapy and Association with Healthcare Utilization Among US Adults with Alcohol or Opioid Use Disorder, 2022-2023.Journal of general internal medicine · 2026Article
- Telemedicine and increased retention in medications for opioid use disorder treatment.Addiction science & clinical practice · 2026Article
- Integrated infectious disease and substance use disorder treatment for severe injection-related infections: protocol for the randomized controlled HI-SIRI trial.Addiction science & clinical practice · 2026Article
- Insurance coverage and provision of opioid disorder treatment: Evidence from Medicare.Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe economic costs associated with opioid misuse are immense. Effective interventions for opioid use disorders are available; however, given the scarce resources faced by substance use treatment providers and payers of all kinds, evidence of effectiveness is not always sufficient to encourage adoption of a given therapy-nor should it be. Economic evaluations can provide evidence that will help stakeholders efficiently allocate their resources.
objectiveThe purpose of this study was to review the literature on economic evaluations of opioid use disorder interventions.
methodsWe performed a systematic review of the major electronic databases from inception until August 2015. A sensitive approach was used to ensure a comprehensive list of relevant articles. Given the quality of the existing reviews, we narrowed our search to studies published since 2007. The Drummond checklist was used to evaluate and categorize economic evaluation studies according to their quality.
resultsA total of 98 articles were identified as potentially relevant to the current study. Of these 98 articles, half (n = 49) were included in this study. Six of the included articles were reviews. The remaining 43 articles reported economic evaluation studies of interventions for opioid use disorders. In general, the evidence on methadone maintenance therapy (MMT) supports previous findings that MMT is an economically advantageous opioid use disorder therapy. The economic literature comparing MMT with other opioid use disorder pharmacotherapies is limited, as is the literature on other forms of therapy.
conclusionWith the possible exception of MMT, additional high-quality economic evaluations are needed in order to assess the relative value of existing opioid use disorder interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.